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Background
Infants infected with HIV-1 perinatally, despite single-
dose nevirapine (sd-NVP) prophylaxis, progress rapidly.
Furthermore, non-nucleoside reverse transcriptase inhibi-
tor (NNRTI) resistance mutations, following exposure to
sd-NVP, may have deleterious effects on efficacy of
antiretroviral therapy (ART). Data on treatment outcome
in sub-Saharan African infants exposed to sd-NVP are
therefore urgently required.
Methods
Infants born to HIV-infected mothers in Durban, South
Africa, were tested on days 1 and 28 of life to determine
intrauterine and intrapartum HIV infection, respectively.
HIV-infected infants received randomised immediate or
deferred (once CD4≤0%) 4-drug ART (zidovudine, lami-
vudine, nelfinavir and nevirapine) in a dedicated study
clinic, with free outpatient and inpatient treatment of ill-
ness. Genotyping for NNRTI resistance mutations was
undertaken pre-ART. Monthly follow-up to 1-year post-
ART included viral load (VL) and CD4 count measure-
ment. Adherence was assessed at every appointment by
caregiver verbal recall and by measured medication
returns.
Results
All 63 HIV-infected infants were exposed to sd-NVP. 20/
51 (39%) infants with baseline genotyping results had
NNRTI resistance (most frequently Y181C; 20%). Median
pre-ART viral load was 952,000 copies/mL. 43 infants
were randomised to immediate ART. Of these, 3 were lost
to follow-up pre-ART; 40 started ART (on median day 28;
range 8-164) and 36/40 completed 1 year of ART. 20
infants were randomised to deferred ART. 16 reached the
treatment threshold of CD4≤20% (at median day 99) and
13/16 started ART during infancy (on median day 142;
range 81-227). Verbal and measured adherence was 99%
and 95%, respectively. One year post-ART, 49/49 (100%)
infants had VL<400 copies/mL and 46/49 (94%) had
VL<50 copies/mL; 9 infants (18%) required second-line
ART due to virological failure (n=4), TB treatment (n=4)
or both (n=1). Time to VL<50 correlated with maternal
CD4 (r=−0.42; P=0.005) and infant pre-ART VL (r=0.64;
P<0.001). NNRTI mutations had no significant effect on
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virological suppression. Infants starting immediate com-
pared to deferred ART had fewer illness episodes (median
7 vs 12 illness episodes per infant; P=0.003), but no sig-
nificant difference in mortality, virological suppression or
CD4 repletion.
Conclusions
Excellent adherence and virological suppression are
achievable in infants, despite high-frequency NNRTI
mutations, high viral loads and rapid disease progression.
Infants are currently relatively neglected in roll-out pro-
grammes and ART provision must be expanded. Immedi-
ate therapy may be preferable to delayed ART, to reduce
morbidity and prevent loss to follow-up.Page 2 of 2
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